Jan Musiałkiewicz

Dr. Jan Musiałkiewicz

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
PKPaweł Komarnicki
Paweł Komarnicki
AMAdam Maciejewski
Adam Maciejewski
JMJan Musiałkiewicz
Jan Musiałkiewicz
MCMichalina Czupińsla
Michalina Czupińsla
George MastorakosGeorge Mastorakos
George Mastorakos
PGPaweł Gut
Paweł Gut
Background : Neuroendocrine tumors (NETs) remain a problematic area in endocrine oncology due to their non-specific symptoms and lack of reliable biomarkers. Visfatin/eNAMPT’s involvement in tumorigenesis has been described in several malignancies. In NETs, NAMPT inhibition was explored as a potential therapeutic option; however, serum visfatin and its role as a biomarker have not been studied. Objectives: We aimed to measure serum visfatin concentrations in NETs and evaluate visfatin’s potential as a diagnostic biomarker. Methods: We conducted a single-center, cross-sectional study of 77 patients with NETs (33 pancreatic and 44 small intestinal) and 29 controls. Patient demographics, tumor characteristics, and clinical data were analyzed, and serum visfatin levels were measured using ELISA. Statistical analyses were performed in Python, including Mann–Whitney U and Kruskal–Wallis tests, Spearman’s correlation, multiple linear regression, and ROC curve analysis. Results: Serum visfatin was higher in NETs compared to controls (median [IQR]: 6.94 [2.11–236.17] vs. 1.59 [1.1–9.24] ng/mL, p = 0.004). ROC curves showed moderate diagnostic performance (AUC = 0.68), with concentrations above 2.11 ng/mL achieving 75.3% sensitivity and 58.6% specificity. In NETs, visfatin did not differ based on WHO grade (G1/G2, p = 0.31), primary site (pancreas/small intestine, p = 0.95), sex (p = 0.89), age (p = 0.13), and when stratified by primary site and grade (p = 0.18). Multiple linear regression confirmed no association between visfatin and the study variables (R-squared = 0.036, all p > 0.2). Conclusions: This is the first study examining serum visfatin as a diagnostic biomarker in NETs. Visfatin concentrations show moderate discriminatory ability between NETs and controls, independent of tumor and clinical characteristics. Further research should involve larger cohorts and comparisons to established biomarkers.

29 August 2025 in Endocrine Connections
Verified
Journal Article
Open access
JMJan Musiałkiewicz
Jan Musiałkiewicz
MRMarek Ruchała
Marek Ruchała
PKPaweł Komarnicki
Paweł Komarnicki
AMAdam Maciejewski
Adam Maciejewski
JSJoanna Sienkiewicz
Joanna Sienkiewicz
PGPaweł Gut
Paweł Gut
Graphical Background: Neuroendocrine tumours (NETs) are a heterogeneous group of rare neoplasms arising from neuroendocrine cells, most commonly found in the gastrointestinal tract and pancreas. Despite novel diagnostic techniques, identifying reliable biomarkers for NETs still remains a challenge. Objectives: Our study explores the diagnostic, monitoring and prognostic value of alpha-fetoprotein (AFP) in pancreatic NETs. Materials and methods: We recruited 41 adult patients diagnosed with liver-metastatic non-functioning pancreatic NETs. Serum AFP levels were assessed at 3-month intervals over a span of 4 years. For comparative purposes, we analysed data in relation to sex, age, liver tumour burden (LTB; <10%, 10–25%), tumour grade based on the WHO 2022 classification (G1, G2), and treatment response at baseline as defined by RECIST 1.1 criteria (SD – stable disease, PD – progressive disease). Every patient underwent treatment with somatostatin analogues during the study period. Results: Elevated AFP concentrations showed a continuous upward trend across all participants and were significantly associated with indicators of more aggressive disease: greater LTB (10–25%, P < 0.001), higher tumour grade (G2, P < 0.001), and progression of disease (PD, P < 0.001). No statistically significant differences in AFP levels were observed in relation to age or sex. Conclusion: AFP consistently increases in patients with progressive pancreatic NETs compared to patients with SD at baseline. The potential utility of AFP measurements requires further follow-up studies, especially as a prognostic biomarker.

8 October 2025 in The American Journal of Medicine
Verified
Journal Article
Closed access
JMJan Musiałkiewicz
Jan Musiałkiewicz
PKPaweł Komarnicki
Paweł Komarnicki
JKJoanna Kapturzak
Joanna Kapturzak
AMAdam Maciejewski
Adam Maciejewski
SSSebastian Sowier
Sebastian Sowier
MRMarek Ruchała
Marek Ruchała

Verified
Journal Article
Open access
PDF file
JMJan Musiałkiewicz
Jan Musiałkiewicz
BBBartlomiej Budny
Bartlomiej Budny
AAAleksandra Anioła
Aleksandra Anioła
AMAdam Maciejewski
Adam Maciejewski
PKPaweł Komarnicki
Paweł Komarnicki
MRMarek Ruchala
Marek Ruchala
Neuroendocrine tumors (NETs) constitute a heterogeneous and predominantly malignant group of neuroendocrine neoplasms that arise from endocrine cells dispersed throughout the body. Their clinical presentation, biological behavior, prognosis, and therapeutic management vary considerably depending on the primary tumor location and hormonal activity. Despite substantial progress in understanding the biology of NETs, identifying reliable molecular biomarkers for diagnosis, prognosis, and prediction of treatment response remains a major challenge. Increasing attention has therefore been devoted to the molecular characterization of NETs, with particular focus on recurrent genetic alterations that may contribute to tumor initiation and progression. In this review, we summarize current knowledge and recent findings referring to certain genes involved in the tumorigenesis of pancreatic and intestinal neuroendocrine tumors. We chose the genes based on data from the COSMIC (Catalogue of Somatic Mutations in Cancer) database, which compiles somatic mutations identified across numerous human cancers. We outline the biological functions of these changes and discuss their potential prognostic and predictive role as molecular markers. We also discuss their clinical relevance in both sporadic and familial forms of NETs, alongside their implications for future research and personalized management strategies.